SQZ Biotechnologies (NYSE:SQZ) Short Interest Down 20.1% in August

SQZ Biotechnologies (NYSE:SQZ) was the target of a large drop in short interest during the month of August. As of August 31st, there was short interest totalling 1,230,000 shares, a drop of 20.1% from the August 15th total of 1,540,000 shares. Currently, 6.5% of the shares of the company are sold short. Based on an average daily trading volume, of 174,200 shares, the short-interest ratio is currently 7.1 days.

Several institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System raised its holdings in shares of SQZ Biotechnologies by 18.5% during the first quarter. California State Teachers Retirement System now owns 7,979 shares of the company’s stock valued at $109,000 after acquiring an additional 1,243 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of SQZ Biotechnologies by 313.9% during the second quarter. Legal & General Group Plc now owns 1,817 shares of the company’s stock valued at $26,000 after acquiring an additional 1,378 shares during the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of SQZ Biotechnologies by 378.6% during the second quarter. Ameritas Investment Partners Inc. now owns 1,785 shares of the company’s stock valued at $26,000 after acquiring an additional 1,412 shares during the last quarter. New York State Common Retirement Fund raised its holdings in shares of SQZ Biotechnologies by 85.7% during the first quarter. New York State Common Retirement Fund now owns 3,900 shares of the company’s stock valued at $53,000 after acquiring an additional 1,800 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in shares of SQZ Biotechnologies by 5.1% during the second quarter. SG Americas Securities LLC now owns 42,533 shares of the company’s stock valued at $615,000 after acquiring an additional 2,078 shares during the last quarter. 47.99% of the stock is owned by institutional investors and hedge funds.

SQZ traded up $0.27 during trading on Wednesday, hitting $15.06. The company’s stock had a trading volume of 6 shares, compared to its average volume of 168,247. SQZ Biotechnologies has a twelve month low of $11.15 and a twelve month high of $36.49. The firm has a market capitalization of $422.39 million and a price-to-earnings ratio of -1.58. The business’s fifty day simple moving average is $13.18 and its 200 day simple moving average is $13.35.

SQZ Biotechnologies (NYSE:SQZ) last released its earnings results on Tuesday, August 3rd. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.11). The company had revenue of $4.54 million for the quarter, compared to analysts’ expectations of $6.24 million. SQZ Biotechnologies had a negative return on equity of 74.70% and a negative net margin of 346.39%. Equities research analysts forecast that SQZ Biotechnologies will post -2.56 earnings per share for the current year.

About SQZ Biotechnologies

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.

Featured Article: What is Net Asset Value (NAV)?

Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.